If you had told someone in the 1980s that we would still be writing about AIDS in 2026, they would have been exhausted. If you told them that we would be close to ending it, they wouldn’t have believed you.

We are not at the end of AIDS. But we are finally, painfully, at the beginning of the end.

In 2026, the largest cohort of people living with HIV in North America and Western Europe are over 55 years old.

We have the tools. We have the science. We have a generation of young people who are sexually liberated and medically literate. What we lack is the collective will to fund the boring logistics of the last mile.

Here is the state of play.

However, there is a quieter revolution happening: A new heat-stable monoclonal antibody was added to drinking water purification systems in two pilot districts in sub-Saharan Africa. Early data suggests a 90% reduction in transmission. If this holds, 2026 will be remembered as the year we stopped treating the virus and started engineering it out of the ecosystem.

In Eastern Europe and Central Asia, infection rates are rising —not falling. Why? Geopolitics. The disruption of global supply chains (exacerbated by the economic volatility of the mid-2020s) has pushed HIV treatment to the bottom of the national priority list.

As we move through 2026, the global health community has hit a strange inflection point. We are no longer talking about "dying from AIDS" in the same way we talked about it ten years ago. We are talking about a new, quieter crisis: The Last Mile Problem.